Skip to Main Content

INFORMATION FOR

Nazli Dizman, MD

Hospital Resident

Contact Information

Nazli Dizman, MD

Coauthors

Selected Publications

  • 437 Safety and efficacy of immune checkpoint inhibitors (ICI) in patients living with HIV (PLWH) and metastatic non-small cell lung cancer (NSCLC): a matched cohort study from the international CATCH-IT consortiumZarif T, Nassar A, Adib E, Fitzgerald B, Huang J, Mouhieddine T, Nonato T, McKay R, Li M, Mittra A, Owen D, Lorentsen M, Dittus C, Dizman N, Emu B, Falohun A, Abdel-Wahab N, Bankapur A, Reed A, Dobbs R, Kim C, Arora A, Shah N, El-Am E, Kozaily E, Abdallah W, Al-Hader A, Ghazal B, Saeed A, Drolen C, Lechner M, Espinar J, Nebhan C, Johnson D, Haykal T, Morse M, Cortellini A, Pinato D, Pria A, Bower M, Hall E, Bakalov V, Bahary N, Rajkumar A, Mangla A, Shah V, Singh P, Nana F, Lia N, Dima D, Funchain P, Saleem R, Woodford R, Long AO G, Menzies A, Genova C, Barletta G, Puri S, Florou V, Idossa D, Queirolo P, Lamberti G, Addeo A, Bersanelli M, Freeman D, Xie W, Ramaswami R, Marron T, Choueiri T, Lurain K, Baden L, Sonpavde G, Naqash A. 437 Safety and efficacy of immune checkpoint inhibitors (ICI) in patients living with HIV (PLWH) and metastatic non-small cell lung cancer (NSCLC): a matched cohort study from the international CATCH-IT consortium 2022, a457-a458. DOI: 10.1136/jitc-2022-sitc2022.0437.
  • 810 Novel renal cell carcinoma immunotherapy combining TLR9-targeted STAT3 antisense oligonucleotide with PD-1 blockadeAlcantara M, Chehrazi-Raffle A, Dizman N, Tang W, Meza L, Zengin Z, Wang D, Moreira D, Horsager A, Hsu J, Pal S, Kortylewski M. 810 Novel renal cell carcinoma immunotherapy combining TLR9-targeted STAT3 antisense oligonucleotide with PD-1 blockade 2022, a845-a845. DOI: 10.1136/jitc-2022-sitc2022.0810.
  • 880 Activation of STAT3 signaling is associated with resistance to immune checkpoint inhibitors in patients (pts) with metastatic renal cell carcinoma (mRCC)Chehrazi-Raffle A, Alcantara M, Dizman N, Tang W, Meza L, Zengin Z, Wang D, Moreira D, Castro D, Govindarajan A, Horsager A, Hsu J, Pal S, Kortylewski M. 880 Activation of STAT3 signaling is associated with resistance to immune checkpoint inhibitors in patients (pts) with metastatic renal cell carcinoma (mRCC) 2022, a916-a916. DOI: 10.1136/jitc-2022-sitc2022.0880.
  • Cabozantinib safety with different anticoagulants in patients with renal cell carcinomaShayeb A, McManus H, Urman D, Jani C, Zhang T, Dizman N, Meza L, Sivakumar A, Gan C, Barata P, Bilen M, Gao X, Heng D, Pal S, Narra R, Kilari D, Kaymakcalan M, McGregor B, Choueiri T, McKay R. Cabozantinib safety with different anticoagulants in patients with renal cell carcinoma Clinical Genitourinary Cancer 2022 DOI: 10.1016/j.clgc.2022.10.013.
  • 1479P Ultra-sensitive circulating tumor DNA (ctDNA) assay distinguishes partial response (PR) and complete response (CR) with immunotherapy in metastatic renal cell carcinoma (mRCC)Chehrazi-Raffle A, Muddasani R, Dizman N, Hsu J, Meza L, Zengin Z, Malhotra J, Chawla N, Lyou Y, Dorff T, Contente-Cuomo T, Dinwiddie D, McDonald B, Trent J, Murtaza M, Pal S. 1479P Ultra-sensitive circulating tumor DNA (ctDNA) assay distinguishes partial response (PR) and complete response (CR) with immunotherapy in metastatic renal cell carcinoma (mRCC) Annals Of Oncology 2022, 33: s1223. DOI: 10.1016/j.annonc.2022.07.1582.
  • Abstract 6293: Genomic characteristics of nivolumab/ipilimumab with or without CBM-588 supplementation in patients with metastatic renal cell carcinomaCastro D, Dizman N, Zengin Z, Malhotra J, Meza L, Muddasani R, Govindarajan A, Chawla N, Chehrazi-Raffle A, Hsu J, Bergerot P, Bergerot C, Dorff T, Lyou Y, Pal S. Abstract 6293: Genomic characteristics of nivolumab/ipilimumab with or without CBM-588 supplementation in patients with metastatic renal cell carcinoma Cancer Research 2022, 82: 6293-6293. DOI: 10.1158/1538-7445.am2022-6293.
  • Self-identification of gender and race/ethnicity in hematology and oncology journal editorial boards: What is the state of diversity?Riano I, Patel S, Abuali I, Ai A, Geiger G, Pimienta J, Ramirez Roggio A, Dhawan N, Dizman N, Salinas A, Duma N. Self-identification of gender and race/ethnicity in hematology and oncology journal editorial boards: What is the state of diversity? Journal Of Clinical Oncology 2022, 40: 11058-11058. DOI: 10.1200/jco.2022.40.16_suppl.11058.
  • Pan-cancer (ca) analysis of the safety and efficacy of immune checkpoint inhibitors (ICI) in patients (pts) living with HIV (PLWH): Results from the international CATCH-IT consortium.El Zarif T, Nassar A, Adib E, Huang J, McKay R, Dobbs R, Dizman N, Drolen C, Kozaily E, Saeed A, Nebhan C, Lorentsen M, Baena J, Dalla Pria A, Baden L, Ramaswami R, Choueiri T, Lurain K, Sonpavde G, Naqash A. Pan-cancer (ca) analysis of the safety and efficacy of immune checkpoint inhibitors (ICI) in patients (pts) living with HIV (PLWH): Results from the international CATCH-IT consortium. Journal Of Clinical Oncology 2022, 40: 2649-2649. DOI: 10.1200/jco.2022.40.16_suppl.2649.
  • Comparison of methodology in the collection of gender and race/ethnicity in hematology and oncology journal editorial boards.Patel S, Riano I, Abuali I, Ai A, Geiger G, Pimienta J, Ramirez Roggio A, Dhawan N, Salinas A, Duma N, Dizman N. Comparison of methodology in the collection of gender and race/ethnicity in hematology and oncology journal editorial boards. Journal Of Clinical Oncology 2022, 40: 11061-11061. DOI: 10.1200/jco.2022.40.16_suppl.11061.
  • Characterization of the microbial resistome in a prospective trial of CBM588 in metastatic renal cell carcinoma (mRCC) offers mechanism for interplay between antibiotic (abx) use and immune checkpoint inhibitor (ICI) activity.Dizman N, Meza L, Bergerot P, Dorff T, Lyou Y, Frankel P, Llamas M, Hsu J, Zengin Z, Malhotra J, Govindarajan A, Castro D, Gillece J, Reining L, Trent J, Takahashi M, Oka K, Higashi S, Highlander S, Pal S. Characterization of the microbial resistome in a prospective trial of CBM588 in metastatic renal cell carcinoma (mRCC) offers mechanism for interplay between antibiotic (abx) use and immune checkpoint inhibitor (ICI) activity. Journal Of Clinical Oncology 2022, 40: 4510-4510. DOI: 10.1200/jco.2022.40.16_suppl.4510.
  • Transcriptomic profiling identifies genomic markers associated with benefit from stereotactic body radiation therapy (SBRT) in oligoprogressive metastatic renal cell carcinoma (mRCC).Zengin Z, Govindarajan A, Muddasani R, Salgia N, Sayegh N, Tripathi N, Salgia S, Meza L, Zhang J, Chawla N, Chehrazi-Raffle A, Malhotra J, Dizman N, Hsu J, Castro D, Byron S, Dandapani S, Pal S. Transcriptomic profiling identifies genomic markers associated with benefit from stereotactic body radiation therapy (SBRT) in oligoprogressive metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2022, 40: 4555-4555. DOI: 10.1200/jco.2022.40.16_suppl.4555.
  • A phase I trial to evaluate the biologic effect of CBM588 ( Clostridium butyricum ) in combination with cabozantinib plus nivolumab for patients with metastatic renal cell carcinoma (mRCC).Meza L, Malhotra J, Zengin Z, Dizman N, Hsu J, Chawla N, Chehrazi-Raffle A, Muddasani R, Govindarajan A, Castro D, Dorff T, Lyou Y, Frankel P, Pal S. A phase I trial to evaluate the biologic effect of CBM588 ( Clostridium butyricum ) in combination with cabozantinib plus nivolumab for patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2022, 40: tps4606-tps4606. DOI: 10.1200/jco.2022.40.16_suppl.tps4606.
  • Distinct outcomes in Hispanic/Latinx and non-Hispanic/Latinx patients with metastatic renal cell carcinoma (mRCC) treated with first-line ipilimumab plus nivolumab (ipi/nivo).Ali S, Leong S, Meza L, Dizman N, Zengin Z, Kim T, Pak Y, Onyshchenko M, Pal S, Chehrazi-Raffle A. Distinct outcomes in Hispanic/Latinx and non-Hispanic/Latinx patients with metastatic renal cell carcinoma (mRCC) treated with first-line ipilimumab plus nivolumab (ipi/nivo). Journal Of Clinical Oncology 2022, 40: 4554-4554. DOI: 10.1200/jco.2022.40.16_suppl.4554.
  • Waning efficacy of COVID-19 vaccination at six months in patients (pts) with genitourinary malignancies.Zengin Z, Meza L, Malhotra J, Salgia S, Ely J, Hsu J, Kelley E, Mead H, Dizman N, Chehrazi-Raffle A, Govindarajan A, Muddasani R, Chawla N, Dorff T, Lyou Y, Karczewska E, Trent J, Salgia R, Altin J, Pal S. Waning efficacy of COVID-19 vaccination at six months in patients (pts) with genitourinary malignancies. Journal Of Clinical Oncology 2022, 40: 185-185. DOI: 10.1200/jco.2022.40.6_suppl.185.
  • Characteristics associated with common reasons to pursue genomic profiling among patients with metastatic genitourinary cancers.Malhotra J, Philip E, Govindarajan A, Salgia S, Meza L, Zengin Z, Muddasani R, Chawla N, Castro D, Chehrazi-Raffle A, Dizman N, Bergerot P, Hsu J, Dorff T, Pal S, Bergerot C. Characteristics associated with common reasons to pursue genomic profiling among patients with metastatic genitourinary cancers. Journal Of Clinical Oncology 2022, 40: 327-327. DOI: 10.1200/jco.2022.40.6_suppl.327.
  • Prolonging utilization of systemic therapy in oligoprogressive metastatic renal cell carcinoma using stereotactic body radiation therapy.Muddasani R, Govindarajan A, Salgia S, Salgia N, Zengin Z, Meza L, Hsu J, Chehrazi-Raffle A, Dizman N, Chawla N, Malhotra J, Bergerot C, Philip E, Castro D, Dandapani S, Tripathi N, Sayegh N, Pal S. Prolonging utilization of systemic therapy in oligoprogressive metastatic renal cell carcinoma using stereotactic body radiation therapy. Journal Of Clinical Oncology 2022, 40: 336-336. DOI: 10.1200/jco.2022.40.6_suppl.336.
  • Nivolumab/ipilimumab with or without CBM588 in metastatic renal cell carcinoma: A randomized phase Ib study and the evolution of the functionality of microbial communities with treatment.Dizman N, Meza L, Bergerot P, Alcantara M, Dorff T, Lyou Y, Frankel P, Llamas M, Hsu J, Zengin Z, Malhotra J, Gillece J, Reining L, Trent J, Takahashi M, Oka K, Higashi S, Highlander S, Pal S. Nivolumab/ipilimumab with or without CBM588 in metastatic renal cell carcinoma: A randomized phase Ib study and the evolution of the functionality of microbial communities with treatment. Journal Of Clinical Oncology 2022, 40: 371-371. DOI: 10.1200/jco.2022.40.6_suppl.371.
  • Intestinal microbiome associated with development of grade 3/4 adverse in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (N/I) and probiotic support: Results from a phase Ib study.Meza L, Dizman N, Bergerot P, Dorff T, Lyou Y, Frankel P, Llamas M, Hsu J, Zengin Z, Salgia N, Malhotra J, Chawla N, Gillece J, Reining L, Trent J, Takahashi M, Oka K, Higashi S, Highlander S, Pal S. Intestinal microbiome associated with development of grade 3/4 adverse in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (N/I) and probiotic support: Results from a phase Ib study. Journal Of Clinical Oncology 2022, 40: 374-374. DOI: 10.1200/jco.2022.40.6_suppl.374.
  • Association between TERT promoter mutations and clinical outcome with immune checkpoint inhibitor therapy for advanced urothelial cancer.Chawla N, Tripathi N, Sayegh N, Govindarajan A, Dizman N, Zengin Z, Meza L, Muddasani R, Chehrazi-Raffle A, Salgia S, Malhotra J, Hsu J, Philip E, Bergerot C, Lyou Y, Swami U, Gupta S, Maughan B, Agarwal N, Pal S. Association between TERT promoter mutations and clinical outcome with immune checkpoint inhibitor therapy for advanced urothelial cancer. Journal Of Clinical Oncology 2022, 40: 561-561. DOI: 10.1200/jco.2022.40.6_suppl.561.
  • Characterization of aberrant alternative splicing landscape in patients with renal cell carcinoma (RCC).Govindarajan A, Hegde A, Chawla N, Dizman N, Zengin Z, Meza L, Muddasani R, Chehrazi-Raffle A, Malhotra J, Castro D, Salgia S, Bergerot C, Tripathi N, Sayegh N, Philip E, Hsu J, Byron S, Pirrotte P, Pal S. Characterization of aberrant alternative splicing landscape in patients with renal cell carcinoma (RCC). Journal Of Clinical Oncology 2022, 40: 386-386. DOI: 10.1200/jco.2022.40.6_suppl.386.
  • Changes in perception of immunotherapy over time among patients with advanced genitourinary cancers.Malhotra J, Philip E, Govindarajan A, Meza L, Zengin Z, Salgia S, Muddasani R, Chawla N, Castro D, Chehrazi-Raffle A, Dizman N, Bergerot P, Hsu J, Dorff T, Pal S, Bergerot C. Changes in perception of immunotherapy over time among patients with advanced genitourinary cancers. Journal Of Clinical Oncology 2022, 40: 328-328. DOI: 10.1200/jco.2022.40.6_suppl.328.
  • Association of intra-tumoral microbiome and response to immune checkpoint inhibitors (ICIs) in patients with metastatic renal cell carcinoma (mRCC).Meza L, Choi Y, Govindarajan A, Dizman N, Zengin Z, Hsu J, Salgia N, Salgia S, Malhotra J, Chawla N, Chehrazi-Raffle A, Muddasani R, Castro D, Chan A, Zhang G, Byron S, Highlander S, Schork N, Pal S. Association of intra-tumoral microbiome and response to immune checkpoint inhibitors (ICIs) in patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2022, 40: 372-372. DOI: 10.1200/jco.2022.40.6_suppl.372.
  • 1564MO Characterization of COVID-19 vaccination response by antibody (Ab) titer and T-cell receptor (TCR) sequencing in patients (pts) with advanced genitourinary (GU) cancersSalgia S, Malhotra J, Zengin Z, Meza L, Ely J, Hsu J, Kelley E, Chehrazi-Raffle A, Govindarajan A, Muddasani R, Salgia N, Dizman N, Chawla N, Dorff T, Lyou Y, Karczewska E, Trent J, Salgia R, Altin J, Pal S. 1564MO Characterization of COVID-19 vaccination response by antibody (Ab) titer and T-cell receptor (TCR) sequencing in patients (pts) with advanced genitourinary (GU) cancers Annals Of Oncology 2021, 32: s1132. PMCID: PMC8454399, DOI: 10.1016/j.annonc.2021.08.1557.
  • 1759MO Associations between sarcopenia and gut microbiota in patients (pts) with metastatic renal cell carcinoma (mRCC) and breast cancer (BC)Zengin Z, Malhotra J, Salgia S, Dizman N, Yost S, Chawla N, Govindarajan A, Hsu J, Salgia N, Bergerot P, Meza L, Chehrazi-Raffle A, Muddasani R, Gillece J, Yuan Y, Highlander S, Pal S. 1759MO Associations between sarcopenia and gut microbiota in patients (pts) with metastatic renal cell carcinoma (mRCC) and breast cancer (BC) Annals Of Oncology 2021, 32: s1211. DOI: 10.1016/j.annonc.2021.08.1704.
  • Treatment outcomes in renal cell carcinoma patients with metastases to the pancreas and other sites.Duarte C, Beuselinck B, Weise N, Dizman N, Collier K, Li H, Chanza N, Elias R, Rose T, Brugarolas J, Agarwal N, Mortazavi A, Pal S, McKay R, Hu J, Lam E. Treatment outcomes in renal cell carcinoma patients with metastases to the pancreas and other sites. Journal Of Clinical Oncology 2021, 39: 4557-4557. DOI: 10.1200/jco.2021.39.15_suppl.4557.
  • The impact of antibiotic (Ab) exposure on clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or VEGF targeted therapy (VEGF-TT).Ernst M, Alaiwi S, Dizman N, Labaki C, Nuzzo P, Adib E, Schmidt A, Meza L, Gan C, Wells J, Bakouny Z, Pal S, Choueiri T, Heng D, Dudani S. The impact of antibiotic (Ab) exposure on clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or VEGF targeted therapy (VEGF-TT). Journal Of Clinical Oncology 2021, 39: 4552-4552. DOI: 10.1200/jco.2021.39.15_suppl.4552.
  • Bridging the gaps between tertiary and community care networks: Results from a southern California survey research analysis.Chehrazi-Raffle A, Salgia N, Hsu J, Zengin Z, Salgia S, Chawla N, Malhotra J, Dizman N, Muddasani R, Meza L, Cianfrocca M, Gong J, Anand S, Chiu V, Yeh J, Pal S. Bridging the gaps between tertiary and community care networks: Results from a southern California survey research analysis. Journal Of Clinical Oncology 2021, 39: 1538-1538. DOI: 10.1200/jco.2021.39.15_suppl.1538.
  • Where are the women and underrepresented minorities in medicine? Race/ethnicity and gender representation in oncology journals’ editorial boards.Patel S, Riano I, Geiger G, Pimienta J, Abuali I, Ai A, Roggio A, Dhawan N, Dizman N, Salinas A, Duma N. Where are the women and underrepresented minorities in medicine? Race/ethnicity and gender representation in oncology journals’ editorial boards. Journal Of Clinical Oncology 2021, 39: 11007-11007. DOI: 10.1200/jco.2021.39.15_suppl.11007.
  • First results of a randomized phase IB study comparing nivolumab/ipilimumab with or without CBM-588 in patients with metastatic renal cell carcinoma.Meza L, Dizman N, Bergerot P, Dorff T, Lyou Y, Frankel P, Mira V, Llamas M, Hsu J, Zengin Z, Salgia N, Salgia S, Malhotra J, Chawla N, Chehrazi-Raffle A, Gillece J, Reining L, Trent J, Highlander S, Pal S. First results of a randomized phase IB study comparing nivolumab/ipilimumab with or without CBM-588 in patients with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2021, 39: 4513-4513. DOI: 10.1200/jco.2021.39.15_suppl.4513.
  • First assessment of the stool mycobiome in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving targeted therapy (TT) or immunotherapy (IO).Dizman N, Hsu J, Gillece J, Folkerts M, Reining L, Bergerot P, Meza L, Zengin Z, Muddasani R, Chawla N, Karimi M, Trent J, Highlander S, Pal S. First assessment of the stool mycobiome in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving targeted therapy (TT) or immunotherapy (IO). Journal Of Clinical Oncology 2021, 39: 337-337. DOI: 10.1200/jco.2021.39.6_suppl.337.
  • Associations between plasma cytokine levels and gut microbiota composition in metastatic renal cell carcinoma (mRCC).Chehrazi-Raffle A, Dizman N, Bergerot P, Karimi M, Hsu J, Gillece J, Folkerts M, Reining L, Highlander S, Pal S. Associations between plasma cytokine levels and gut microbiota composition in metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2021, 39: 351-351. DOI: 10.1200/jco.2021.39.6_suppl.351.
  • Distinct cytokines predict response to immunotherapy and targeted therapy in metastatic renal cell carcinoma (mRCC).Chehrazi-Raffle A, Meza L, Alcantara M, Salgia N, Dizman N, Bergerot P, Hsu J, Kortylewski M, Pal S. Distinct cytokines predict response to immunotherapy and targeted therapy in metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2021, 39: 352-352. DOI: 10.1200/jco.2021.39.6_suppl.352.
  • Evaluation of cabozantinib (cabo) in combination with direct oral anticoagulants (DOAC) or low molecular weight heparin (LMWH) in renal cell carcinoma (RCC).Mesleh Shayeb A, Urman D, Dizman N, Meza L, Sivakumar A, Gan C, Dzimitrowicz H, Zhang T, Barata P, Bilen M, Gao X, Heng D, Pal S, Kaymakcalan M, McGregor B, Choueiri T, McKay R. Evaluation of cabozantinib (cabo) in combination with direct oral anticoagulants (DOAC) or low molecular weight heparin (LMWH) in renal cell carcinoma (RCC). Journal Of Clinical Oncology 2021, 39: 291-291. DOI: 10.1200/jco.2021.39.6_suppl.291.
  • Radiomic features of renal cell carcinoma primary and metastatic sites as predictors of TERT and BAP1 mutations.Meza L, Filippov A, Naim S, Dizman N, Chehrazi-Raffle A, Philip E, Maholtra J, Muddasani R, Chawla N, Wong C, Salgia S, Karimi M, Trent J, Byron S, Chaudhry A, Pal S. Radiomic features of renal cell carcinoma primary and metastatic sites as predictors of TERT and BAP1 mutations. Journal Of Clinical Oncology 2021, 39: 282-282. DOI: 10.1200/jco.2021.39.6_suppl.282.
  • 645 Preclinical development of a novel colon-targeted therapeutic for the treatment of immune checkpoint inhibitor (ICI)-colitisDizman N, Greenberg M, Newman A, Skupsky J, Hsu J, Zengin Z, Salgia N, Meza L, Chawla N, Salgia S, Malhotra J, Pal S. 645 Preclinical development of a novel colon-targeted therapeutic for the treatment of immune checkpoint inhibitor (ICI)-colitis Journal For ImmunoTherapy Of Cancer 2020, 8: a682-a682. DOI: 10.1136/jitc-2020-sitc2020.0645.
  • Efficacy And Toxicity Of Radiotherapy For Oligoprogression Of Metastatic Renal Cell carcinoma (mRCC)Dandapani S, Salgia N, Dizman N, Zengin Z, Hsu J, Pal S. Efficacy And Toxicity Of Radiotherapy For Oligoprogression Of Metastatic Renal Cell carcinoma (mRCC) International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e879. DOI: 10.1016/j.ijrobp.2020.07.468.
  • Race/Ethnicity and Survival in Metastatic Renal Cell Carcinoma: Outcomes for Patients Receiving First Line Targeted TherapiesDizman N, Salgia N, Bergerot P, Hsu J, Ruel N, Pal S. Race/Ethnicity and Survival in Metastatic Renal Cell Carcinoma: Outcomes for Patients Receiving First Line Targeted Therapies Kidney Cancer 2020, 4: 159-166. DOI: 10.3233/kca-200092.
  • Abstract 5426: Genomic and immunohistochemical characterization of patients with advanced papillary renal cell carcinoma: Focus on exceptional respondersSalgia N, Dizman N, Mambetsariev I, Mirzapoiazova T, Zhao D, Kulkarni P, Salgia R, Pal S. Abstract 5426: Genomic and immunohistochemical characterization of patients with advanced papillary renal cell carcinoma: Focus on exceptional responders Cancer Research 2020, 80: 5426-5426. DOI: 10.1158/1538-7445.am2020-5426.
  • Abstract 1312: Identifying the genomic correlates of clinical benefit (CB) from immunotherapies (IO) and vascular endothelial growth factor-tyrosine kinase inhibitors (VEGF-TKI) in metastatic renal cell carcinoma (mRCC)Dizman N, Byron S, Lyou Y, Bergerot P, Hsu J, Sam A, Trieu D, Trent J, Pal S. Abstract 1312: Identifying the genomic correlates of clinical benefit (CB) from immunotherapies (IO) and vascular endothelial growth factor-tyrosine kinase inhibitors (VEGF-TKI) in metastatic renal cell carcinoma (mRCC) Cancer Research 2020, 80: 1312-1312. DOI: 10.1158/1538-7445.am2020-1312.
  • Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC): An international mRCC database consortium (IMDC) analysis.Araujo D, Wells C, Hansen A, Dizman N, Pal S, Beuselinck B, Donskov F, Gan C, Yan F, Tran B, Kollmannsberger C, de Velasco G, Yuasa T, Reaume M, Ernst D, Powles T, Bjarnason G, Choueiri T, Heng D, Dudani S. Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC): An international mRCC database consortium (IMDC) analysis. Journal Of Clinical Oncology 2020, 38: 5068-5068. DOI: 10.1200/jco.2020.38.15_suppl.5068.
  • Outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first-line Immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials.Gan C, Dudani S, Wells C, Bakouny Z, Dizman N, Pal S, Szabados B, Wood L, Kollmannsberger C, Agarwal N, Donskov F, Basappa N, Bjarnason G, Parnis F, Porta C, Davis I, Vaishampayan U, Kanesvaran R, Choueiri T, Heng D. Outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first-line Immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials. Journal Of Clinical Oncology 2020, 38: 5070-5070. DOI: 10.1200/jco.2020.38.15_suppl.5070.
  • Genomic and transcriptomic correlates of clinical benefit from immunotherapy and targeted therapy among patients with metastatic renal cell carcinoma (mRCC).Salgia N, Dizman N, Lyou Y, Bergerot P, Hsu J, Byron S, Trent J, Pal S. Genomic and transcriptomic correlates of clinical benefit from immunotherapy and targeted therapy among patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2020, 38: 5076-5076. DOI: 10.1200/jco.2020.38.15_suppl.5076.
  • Randomized prospective trial assessing Bifidobacterium -containing probiotic supplementation in metastatic renal cell carcinoma (mRCC) patients receiving vascular endothelial growth factor-tyrosine kinase inhibitors (VEGF-TKIs).Dizman N, Hsu J, Bergerot P, Gillece J, Folkerts M, Reining L, Trent J, Highlander S, Pal S. Randomized prospective trial assessing Bifidobacterium -containing probiotic supplementation in metastatic renal cell carcinoma (mRCC) patients receiving vascular endothelial growth factor-tyrosine kinase inhibitors (VEGF-TKIs). Journal Of Clinical Oncology 2020, 38: 5078-5078. DOI: 10.1200/jco.2020.38.15_suppl.5078.
  • Circulating tumor DNA sequencing analysis of patients with metastatic renal cell carcinoma (mRCC).Zengin Z, Dizman N, Salgia N, Jones J, Zhang J, Liu Y, Xu B, Li F, Wang Y, Li M, Du R, Zhou Y, Hsu J, Salgia M, Yang L, Pal S. Circulating tumor DNA sequencing analysis of patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2020, 38: e17100-e17100. DOI: 10.1200/jco.2020.38.15_suppl.e17100.
  • Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.Dudani S, Gan C, Wells C, Bakouny Z, Dizman N, Pal S, Wood L, Kollmannsberger C, Szabados B, Powles T, Beuselinck B, Donskov F, Hansen A, Bjarnason G, Canil C, Srinivas S, Agarwal N, Liow E, Choueiri T, Heng D. Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes. Journal Of Clinical Oncology 2020, 38: 5063-5063. DOI: 10.1200/jco.2020.38.15_suppl.5063.
  • Prognostic understanding in advanced genitourinary cancer and its association with clinical characteristics.Bergerot C, Philip E, Bergerot P, Salgia N, Salgia M, Hsu J, Dizman N, Pal S. Prognostic understanding in advanced genitourinary cancer and its association with clinical characteristics. Journal Of Clinical Oncology 2020, 38: 665-665. DOI: 10.1200/jco.2020.38.6_suppl.665.
  • Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).Stukalin I, Dudani S, Wells C, Gan C, Pal S, Dizman N, Powles T, Donskov F, Wood L, Bakouny Z, Kollmannsberger C, Basappa N, Hansen A, de Velasco G, Beuselinck B, Canil C, Vaishampayan U, Agarwal N, Choueiri T, Heng D. Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Journal Of Clinical Oncology 2020, 38: 684-684. DOI: 10.1200/jco.2020.38.6_suppl.684.
  • Cabozantinib real-world effectiveness in the first through fourth-line settings for the treatment of metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).Gan C, Dudani S, Wells C, Donskov F, Pal S, Dizman N, Rathi N, Beuselinck B, Yan F, Lalani A, Hansen A, Szabados B, de Velasco G, Tran B, Lee J, Vaishampayan U, Bjarnason G, Subasri M, Choueiri T, Heng D. Cabozantinib real-world effectiveness in the first through fourth-line settings for the treatment of metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Journal Of Clinical Oncology 2020, 38: 639-639. DOI: 10.1200/jco.2020.38.6_suppl.639.
  • A phase I trial to assess the biologic effect of CBM588 ( Clostridium butyricum ) in combination with nivolumab plus ipilimumab (nivo/ipi) in patients with metastatic renal cell carcinoma (mRCC).Bergerot P, Dizman N, Ruel N, Frankel P, Hsu J, Pal S. A phase I trial to assess the biologic effect of CBM588 ( Clostridium butyricum ) in combination with nivolumab plus ipilimumab (nivo/ipi) in patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2020, 38: tps764-tps764. DOI: 10.1200/jco.2020.38.6_suppl.tps764.
  • Exploring motivation to pursue genomic profiling among patients with metastatic genitourinary cancers.Philip E, Bergerot C, Bergerot P, Salgia M, Salgia N, Dizman N, Hsu J, Pal S. Exploring motivation to pursue genomic profiling among patients with metastatic genitourinary cancers. Journal Of Clinical Oncology 2020, 38: 663-663. DOI: 10.1200/jco.2020.38.6_suppl.663.
  • Outcomes of patients with pancreatic-only oligometastatic renal cell carcinoma (RCC).Duarte C, Martinez Chanza N, Collier K, Dizman N, Rathi N, McKay R, Panian J, Narayan V, Carneiro B, Mega A, Hu J, Meguid C, Agarwal N, Pal S, Mortazavi A, Harshman L, Lam E. Outcomes of patients with pancreatic-only oligometastatic renal cell carcinoma (RCC). Journal Of Clinical Oncology 2020, 38: 681-681. DOI: 10.1200/jco.2020.38.6_suppl.681.
  • Progression-free survival (PFS) and overall survival (OS) across ethnicities for patients with metastatic renal cell carcinoma (mRCC) receiving targeted therapies (TT) as first-line (1L) treatment.Salgia N, Dizman N, Bergerot P, Bergerot C, Hsu J, Pal S. Progression-free survival (PFS) and overall survival (OS) across ethnicities for patients with metastatic renal cell carcinoma (mRCC) receiving targeted therapies (TT) as first-line (1L) treatment. Journal Of Clinical Oncology 2020, 38: 645-645. DOI: 10.1200/jco.2020.38.6_suppl.645.
  • Genomic profiling: Shared decision making and emotional well-being among patients with metastatic genitourinary cancers.Bergerot C, Bergerot P, Philip E, Salgia M, Salgia N, Dizman N, Hsu J, Pal S. Genomic profiling: Shared decision making and emotional well-being among patients with metastatic genitourinary cancers. Journal Of Clinical Oncology 2019, 37: 31-31. DOI: 10.1200/jco.2019.37.31_suppl.31.
  • Targeted Therapies Following First-Line Immune Checkpoint Inhibitor Combination in Metastatic Renal Cell Carcinoma: A Single Center ExperienceDizman N, Bergerot P, Bergerot C, Hsu J, Pal S. Targeted Therapies Following First-Line Immune Checkpoint Inhibitor Combination in Metastatic Renal Cell Carcinoma: A Single Center Experience Kidney Cancer 2019, 3: 171-176. DOI: 10.3233/kca-190056.
  • Efficacy of systemic treatment for metastatic renal cell carcinoma (mRCC) guided by comprehensive genomic profiling (CGP).Bergerot P, Bergerot C, Dizman N, Salgia N, Hsu J, Pal S. Efficacy of systemic treatment for metastatic renal cell carcinoma (mRCC) guided by comprehensive genomic profiling (CGP). Journal Of Clinical Oncology 2019, 37: 63-63. DOI: 10.1200/jco.2019.37.27_suppl.63.
  • Comparing clinician- and patient-rated performance status and association with psychosocial status in advanced genitourinary cancer.Bergerot C, Bergerot P, Philip E, Hsu J, Dizman N, Salgia M, Battle D, Vaishampayan U, Loscalzo M, Dale W, Pal S. Comparing clinician- and patient-rated performance status and association with psychosocial status in advanced genitourinary cancer. Journal Of Clinical Oncology 2019, 37: 195-195. DOI: 10.1200/jco.2019.37.27_suppl.195.
  • 2099-P: Assessing the Link between Metabolic Phenotype and Skeletal Muscle Index (SMI) in Obese and Nonobese AdultsONAL-TASTAN Y, DIZMAN N, ERTUR E, CAKIR-GUNEY B, SARGIN M, OGUZ A. 2099-P: Assessing the Link between Metabolic Phenotype and Skeletal Muscle Index (SMI) in Obese and Nonobese Adults Diabetes 2019, 68 DOI: 10.2337/db19-2099-p.
  • Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results.Dizman N, Rosenberg J, Hoffman-Censits J, Quinn D, Petrylak D, Galsky M, Vaishampayan U, De Giorgi U, Gupta S, Burris H, Soifer H, Li G, Dambkowski C, Moran S, Ye Y, Daneshmand S, Bajorin D, Pal S. Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results. Journal Of Clinical Oncology 2019, 37: 4510-4510. DOI: 10.1200/jco.2019.37.15_suppl.4510.
  • First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal-cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC).Dudani S, Graham J, Wells C, Bakouny Z, Pal S, Dizman N, Donskov F, Porta C, de Velasco G, Hansen A, Iafolla M, Beuselinck B, Vaishampayan U, Wood L, Liow E, Yan F, Yuasa T, Bjarnason G, Choueiri T, Heng D. First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal-cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC). Journal Of Clinical Oncology 2019, 37: 4577-4577. DOI: 10.1200/jco.2019.37.15_suppl.4577.
  • Assessment of the androgen receptor (AR) activity score versus AR expression in muscle invasive bladder cancer (MIBC).Bergerot P, Arvinitis L, Dizman N, Salgia M, Pal S, Jones J. Assessment of the androgen receptor (AR) activity score versus AR expression in muscle invasive bladder cancer (MIBC). Journal Of Clinical Oncology 2019, 37: 463-463. DOI: 10.1200/jco.2019.37.7_suppl.463.
  • Expectations of cure among patients with advanced genitourinary cancer treated with immunotherapy.Bergerot C, Bergerot P, Philip E, Hsu J, Dizman N, Vaishampayan U, Dorff T, Pal S. Expectations of cure among patients with advanced genitourinary cancer treated with immunotherapy. Journal Of Clinical Oncology 2019, 37: 591-591. DOI: 10.1200/jco.2019.37.7_suppl.591.
  • First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Preliminary results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).Dudani S, Graham J, Wells C, Pal S, Dizman N, Donskov F, Bjarnason G, Hansen A, Iafolla M, Vaishampayan U, Porta C, Beuselinck B, Yan F, Wood L, Liow E, Kollmannsberger C, Yuasa T, Zhang C, Choueiri T, Heng D. First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Preliminary results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Journal Of Clinical Oncology 2019, 37: 584-584. DOI: 10.1200/jco.2019.37.7_suppl.584.
  • Receipt of systemic therapy in older versus younger patients (pts) with metastatic renal cell carcinoma (mRCC).Hahn A, Haaland B, Rathi N, Dizman N, Maughan B, Pal S, Agarwal N. Receipt of systemic therapy in older versus younger patients (pts) with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2019, 37: 580-580. DOI: 10.1200/jco.2019.37.7_suppl.580.
  • Duration of treatment (DOT) with targeted therapies (TT) or immunotherapy (IO) in PBRM1 mutated metastatic renal cell carcinoma (mRCC).Dizman N, Bergerot P, Bergerot C, Hsu J, Pal S. Duration of treatment (DOT) with targeted therapies (TT) or immunotherapy (IO) in PBRM1 mutated metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2019, 37: 622-622. DOI: 10.1200/jco.2019.37.7_suppl.622.
  • Targeted Therapy and Immunotherapy: Effect of Body Mass Index on Clinical Outcomes in Patients Diagnosed with Metastatic Renal Cell CarcinomaBergerot P, Bergerot C, Philip E, Meza L, Dizman N, Hsu J, Pal S. Targeted Therapy and Immunotherapy: Effect of Body Mass Index on Clinical Outcomes in Patients Diagnosed with Metastatic Renal Cell Carcinoma Kidney Cancer 2019, 3: 63-70. DOI: 10.3233/kca-180047.
  • Frustration and distress during treatment for advanced renal cell carcinoma.Bergerot C, Battle D, Bergerot P, George D, Hammers H, Jonasch E, Ljungberg B, Bex A, Dizman N, Staehler M, Pal S. Frustration and distress during treatment for advanced renal cell carcinoma. Journal Of Clinical Oncology 2018, 36: 47-47. DOI: 10.1200/jco.2018.36.34_suppl.47.
  • Differences in comprehension of somatic genomic profiling between younger and older adults with advanced genitourinary cancer.Bergerot C, Bergerot P, Hsu J, Dizman N, Gray S, Pal S. Differences in comprehension of somatic genomic profiling between younger and older adults with advanced genitourinary cancer. Journal Of Clinical Oncology 2018, 36: 228-228. DOI: 10.1200/jco.2018.36.30_suppl.228.
  • 894P Comparative effect of body-mass index on outcome with targeted therapy and immunotherapy in patients with metastatic renal cell carcinoma (mRCC)Dizman N, Bergerot P, Bergerot C, Philip E, Salgia M, Hsu J, Adashek J, Pal S. 894P Comparative effect of body-mass index on outcome with targeted therapy and immunotherapy in patients with metastatic renal cell carcinoma (mRCC) Annals Of Oncology 2018, 29: viii318. DOI: 10.1093/annonc/mdy283.103.
  • Improving the awareness and clinical practices of healthcare professionalsGonen O, Erbakan A, Mesci B, Dizman N, Oguz A. Improving the awareness and clinical practices of healthcare professionals Clinical Nutrition 2018, 37: s108. DOI: 10.1016/j.clnu.2018.06.1412.
  • Patient-reported frustrations in renal cell carcinoma (RCC) care delivery: Results of a joint European Association of Urology (EAU)/KCCure survey.Bergerot C, Battle D, Bergerot P, George D, Hammers H, Jonasch E, Bex A, Ljungberg B, Dizman N, Pal S, Staehler M. Patient-reported frustrations in renal cell carcinoma (RCC) care delivery: Results of a joint European Association of Urology (EAU)/KCCure survey. Journal Of Clinical Oncology 2018, 36: 4570-4570. DOI: 10.1200/jco.2018.36.15_suppl.4570.
  • Is there a role for immunotherapy (IO) and tyrosine kinase inhibitors (TKI) for older adults with metastatic renal cell carcinoma (mRCC)?Dizman N, Bergerot P, Bergerot C, Hsu J, Adashek J, Dale W, Pal S. Is there a role for immunotherapy (IO) and tyrosine kinase inhibitors (TKI) for older adults with metastatic renal cell carcinoma (mRCC)? Journal Of Clinical Oncology 2018, 36: e22052-e22052. DOI: 10.1200/jco.2018.36.15_suppl.e22052.
  • Association between mutation variant allele fractions (mVAFs) and response to immunotherapy (IO) in metastatic renal cell carcinoma (mRCC).Dizman N, Bergerot P, Bergerot C, Hsu J, Adashek J, Salgia M, Pal S. Association between mutation variant allele fractions (mVAFs) and response to immunotherapy (IO) in metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2018, 36: e16575-e16575. DOI: 10.1200/jco.2018.36.15_suppl.e16575.
  • Abstracts from the Sixteenth International Kidney Cancer Symposium, 2nd-3rd November 2017, Miami, FloridaLee C, Makker V, Rasco D, Taylor M, Dutcus C, Shumaker R, Schmidt E, Stepan D, Li D, Motzer R, Pal S, Puente J, Heng D, Rha S, Stepan D, Dutcus C, Glen H, Grünwald V, Hutson T, Porta C, Powles T, Eto M, Baig M, Dutta L, Choueiri T, Faiena I, Zomorodian N, Comin-Anduix B, Sachdeva A, Bot A, Kabinnavar F, Said J, Cheung-Lau G, Macabali M, Cabrera P, Kaplan-Lefko P, Berent-Maoz B, Pantuck A, Belldegrun A, Drakaki A, Wood L, Allman K, Ornstein M, Martin A, Garcia J, Gilligan T, Grivas P, Company D, Olencki T, Sumanta P, Rathmell W, Rini B, George D, Motzer R, Staehler M, Pandha H, Donskov F, Escudier B, Kliment J, Pantuck A, Patel A, DeAnnuntis L, Bhattacharyya H, Lin X, Lechuga M, Serfass L, Patard J, Ravaud A, Dutcher G, Liu Y, Ravindranathan D, Carthon B, Kissick H, Harris W, Kucuk O, Master V, Bilen M, Dizman N, Poroyko V, Wong H, Bergerot C, Bergerot P, Caitano M, Hsu J, Frankel P, Jones J, Salgia R, Pal S, Proskorovsky I, Benedict A, Negrier S, Cappelleri J, Bargo D, Desai J, Larkin J, Salgia M, Ashing-Giwa K, Cotta B, Sedrak M, Pandey M, Hanif A, Mehta R, Khan S, Azabdaftari G, George S, Koshkin V, Barata P, Zhang T, George D, Atkins M, Kelly W, Vogelzang N, Pal S, Appleman L, Ornstein M, Garcia J, Rini B, Barata P, de Liano A, Mendiratta P, Szabados B, Crolley V, Zanick B, Allman K, Tyler A, Videtic G, DiNatale R, Sanchez A, Blum K, John N, Becerra M, Xie W, Choueiri T, Russo P, Hakimi A, Becerra M, Reznik E, Redzematovic A, Tennenbaum D, Kashan M, Ghanaat M, Casuscelli J, Manley B, Jonsson P, Durack J, Solomon S, Arcila M, Bourque C, Socci N, Carlo M, Voss M, Feldman D, Motzer R, Coleman J, Cheng E, Hsieh J, Doan J, Malcolm B, Valaitis E, Kholfi S, Hoover K, Fishman M, Alter R, Beck J, Joshi M, Zhang X, Glasser C, Mutyaba M, Vidal B, Sherman M, Bhatt R, Plimack E, Group D, Harrison M, Costello B, Bhavsar N, Vaishampayan U, Zakharia Y, Jim H, Fishman M, Molina A, Kyriakopoulos C, Tsao C, Gartrell B, Hussain A, Stadler W, Agarwal N, Pachynski R, Hutson T, Hammers H, Ryan C, Mardekian J, Singh K, Borham A, Fan A, Metzner T, Kino A, Sundaram V, Schmiedeskamp H, Desai M, Kamaya A, Bjarnason G, Kollmannsberger C, Ahmad Q, Dezzani L, Elmeliegy M, Han J, Nathan P, Sullivan J, Ward A, Peneva D, Yang S, Rao S, Figlin R, Ueno D, Xuoquan X, Boeke M, Syed J, Nguyen K, McGillivray P, Adeniran A, Humphrey P, Kluger Y, Lu Z, Shuch B, Mukherjee S, Mandelker D, Vijai J, Kemel Y, Zhang L, Huan K, Coskey D, Pradhan N, Arnold A, Chen Y, Hyman D, Ladanyi M, Cadoo K, Walsh M, Stadler Z, Robson M, Offit K, Pal S, McDermott D, Atkins M, Fong L, Joseph R, Bracarda S, Suarez C, Maio M, Gore M, Grunwald V, Qiu J, Thobhani A, Huseni M, Schiff C, DiNatale R, John N, Liu M, Nixon B, Reuter V, Li M, Derosa L, Routy B, Enot D, Fidelle M, Gubet A, Goldwasser F, Zitvogel L, Loriot Y, Albiges L, Voss M, Kuo F, Marker M, Cheng Y, Patel P, Riaz N, Chan T, Hsieh J, Tannir N, Carrasco-Alfonso M, Sternberg C, Gatto F, Hakimi A, Nielsen J, Hahn A, Gill D, Albertson D, Gowrishankar B, Merriman J, Agarwal A, Thodima V, Harrington E, Au T, Maughan B, Houldsworth J, Stenehjem D, Deshpande C, Solem C, Macahilig C, Jiang S, Hawkins R, Josey J, Shah R, Botteman M, Luo L, Cella D, Blute M, Crispen P, Calabrese C, Wood L, Kirchner E, Tyler A, Profusek P, Allman K, Kontzias A, Calabrese L, McFarlane J, Olsen M, Molina A, Bauer T, Tykodi S, Somer B, Reeves J, Gunuganti V, Page R, Babu S, Van Veldhuizen P, Zhang J, Zhao H, Vogelzang N, Ghiorghiu D, Jakacki R, Haddad V, Kohlmann A, Frigault M, Ottesen L, Cauduro C, Barrios P, Crivelaro P, Doro L, Lenz G, Debiasi M, Fay A, Kotesha R, Angelov L, Chao S, Elson P, Koshkin V, Chen Y, Tullio K, Petruzella S, Samson M, Akin O, Paris M, Mourtzakis M, Hakimi A, Helena F, Abreu D, Gueglio G, Jurado A, Meza L, Scorticati, Lopez M, de Cassio Zequi S, da Costa W, Yandian J, Ubillos L, Ameri C, Nolazco A, Martinez P, Carvalhal G, Barrios P, Bengio R, Arribillaga L, Langenhin R, Muguruza D, Gadu J, Bravo E, Castillejos R, Rodríguez-Covarrubias F, Mingote P, Ginastar N, Puente R, Decia R, Guimarães G, Palau J, Sharma P, Carducci M, Oudard S, Hammers H, Castellano D, Alva A, Richardet M, Chevreau C, Plimack E, Srinivas S, Procopio G, Sosman J, McDermott D, Berghorn E, Yang L, Needle M, Barthelemy P, Lundstam S, Haraldsson B, Stierner U, Nyström J, Madsen A, Bauer T, Voss M, Ernstoff M, Lewis L, Razak A, Spratlin J, Berghorn E, Amin A, Lewis L, Ernstoff M, Knox J, Duzgal C, Blum K, DiNatale R, Ranasinghe B, Benfante N, Coleman J, Kattan M, Ostrovnaya I, Bergerot P, Bergerot C, Zequi S, Fay A, Dara Y, Manuel M, Cotta B, Goncalves E, Formiga M, Tariki M, Clavijo D, Choueiri T, Lopes G, Ball M, An J, Peterson J, Metwalli A, Merino M, Srinivasan R, Linehan W. Abstracts from the Sixteenth International Kidney Cancer Symposium, 2nd-3rd November 2017, Miami, Florida Kidney Cancer 2018, 2: i-s50. PMCID: PMC6179115, DOI: 10.3233/kca-189001.
  • Association of microbiome and plasma cytokine dynamics to nivolumab response in metastatic renal cell carcinoma (mRCC).Maia M, Poroyko V, Won H, Almeida L, Bergerot P, Dizman N, Hsu J, Jones J, Salgia R, Pal S. Association of microbiome and plasma cytokine dynamics to nivolumab response in metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2018, 36: 656-656. DOI: 10.1200/jco.2018.36.6_suppl.656.
  • Gut microbiome composition and response to sunitinib in metastatic renal cell carcinoma (mRCC).Gong J, Dizman N, Poroyko V, Won H, Bergerot C, Bergerot P, Maia M, Hsu J, Frankel P, Jones J, Salgia R, Pal S. Gut microbiome composition and response to sunitinib in metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2018, 36: 657-657. DOI: 10.1200/jco.2018.36.6_suppl.657.
  • Relationship of tumor mutational burden (TMB) to immunotherapy response in metastatic renal cell carcinoma (mRCC).Maia M, Almeida L, Bergerot P, Dizman N, Pal S. Relationship of tumor mutational burden (TMB) to immunotherapy response in metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2018, 36: 662-662. DOI: 10.1200/jco.2018.36.6_suppl.662.
  • Association between circulating tumor DNA (ctDNA) detection and radiographic tumor burden (rTB) in advanced bladder and upper tract (UT) cancer patients.Maia M, Almeida L, Dizman N, Bergerot P, Lanman R, Banks K, Vogelzang N. Association between circulating tumor DNA (ctDNA) detection and radiographic tumor burden (rTB) in advanced bladder and upper tract (UT) cancer patients. Journal Of Clinical Oncology 2018, 36: 485-485. DOI: 10.1200/jco.2018.36.6_suppl.485.
  • Association of somatic mutational burden with depression and anxiety in patients with metastatic urothelial cancer (mUC).Bergerot C, Clark K, Bergerot P, Ashing K, Hahn A, Obenchain R, Dizman N, Hsu J, Philip E, Loscalzo M, Pal S. Association of somatic mutational burden with depression and anxiety in patients with metastatic urothelial cancer (mUC). Journal Of Clinical Oncology 2018, 36: 471-471. DOI: 10.1200/jco.2018.36.6_suppl.471.
  • 1670P Serial genotypic characterization of circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) undergoing treatment with abiraterone acetate (abi) or enzalutamide (enza)Dizman N, Patel J, He M, Foulk B, Smirnov D, Hsu J, Twardowski P, Kortylewski M, Bhargava V, Jones J, Pal S. 1670P Serial genotypic characterization of circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) undergoing treatment with abiraterone acetate (abi) or enzalutamide (enza) Annals Of Oncology 2017, 28: v586. DOI: 10.1093/annonc/mdx390.042.
  • 1427P Biopsychosocial factors underlying older patients treated for an incurable cancer in a two-tiered health care system in BrazilBergerot C, Ashing K, Philip E, Bergerot P, Dizman N, Pal S, Dale W. 1427P Biopsychosocial factors underlying older patients treated for an incurable cancer in a two-tiered health care system in Brazil Annals Of Oncology 2017, 28: v508-v509. DOI: 10.1093/annonc/mdx384.005.
  • 908P Association between biopsychosocial distress (BPSD) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)Bergerot C, Clark K, Ashing K, Almeida L, Bergerot P, Obenchain R, Dizman N, Hsu J, Maia M, Philip E, Loscalzo M, Pal S. 908P Association between biopsychosocial distress (BPSD) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) Annals Of Oncology 2017, 28: v322. DOI: 10.1093/annonc/mdx371.062.
  • Association of circulating tumor DNA (ctDNA) detection in metastatic renal cell carcinoma (mRCC) with tumor burden.Maia M, Bergerot P, Dizman N, Hsu J, Jones J, Choueiri T, Sonpavde G, Lanman R, Banks K, Pal S. Association of circulating tumor DNA (ctDNA) detection in metastatic renal cell carcinoma (mRCC) with tumor burden. Journal Of Clinical Oncology 2017, 35: 4582-4582. DOI: 10.1200/jco.2017.35.15_suppl.4582.
  • 794P Impact of race on survival following radical cystectomy for muscle-invasive bladder cancer (MIBC): Analysis of the US National Cancer Database (NCDB)Dizman N, Pal S, Nelson R, Hsu J, Bergerot P, Nix J, Sonpavde G. 794P Impact of race on survival following radical cystectomy for muscle-invasive bladder cancer (MIBC): Analysis of the US National Cancer Database (NCDB) Annals Of Oncology 2016, 27: vi276. DOI: 10.1093/annonc/mdw373.22.
  • SUN-P130: Awareness of Healthcare Professionals and the Status of their Patients in Nutritional CareGonen O, Bozkurt I, Dizman N, Oguz A. SUN-P130: Awareness of Healthcare Professionals and the Status of their Patients in Nutritional Care Clinical Nutrition 2016, 35: s92. DOI: 10.1016/s0261-5614(16)30473-3.
  • Tuberous Sclerosis Complex Mimicking Autosomal Dominant Polycystic Kidney Disease: A Case ReportAydın Bahat K, Özkök A, Önal Y, Dizman N, Şahin Yıldız B, Şaşak G, Alışır S, Ecder T, Odabaş A. Tuberous Sclerosis Complex Mimicking Autosomal Dominant Polycystic Kidney Disease: A Case Report Turkish Journal Of Nephrology 2016, 25 DOI: 10.5262/tndt.2016.50.